Global Assistive Reproductive Technology Market Growth, Share, Size, Trends and Forecast (2024 - 2030)

This report extensively covers different segments of Global Assistive Reproductive Technology Market and provides an in depth analysis (including revenue analysis for both historic and forecast periods) for all the market segments. In this report, the analysis for every market segment is substantiated with relevant data points and, insights that are generated from analysis of these data points (data trends and patterns).

The market is segmented by product, technology, procedures, and geography, reflecting the diverse array of interventions and approaches available to address infertility and facilitate conception for individuals and couples worldwide. Product segmentation in the ART market encompasses a wide range of medical devices, equipment, and consumables utilized in fertility treatments and procedures. Each product category plays a unique role in the ART process, from stimulating ovulation and harvesting eggs to fertilization, embryo culture, and embryo transfer.

Technology segmentation in the ART market highlights the various assisted reproductive techniques and laboratory procedures employed to overcome infertility challenges and achieve successful pregnancies. Key technologies include in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), gamete intrafallopian transfer (GIFT), intrauterine insemination (IUI), preimplantation genetic testing (PGT), embryo cryopreservation, and sperm or egg donation. These technologies leverage advanced laboratory techniques, instrumentation, and expertise to optimize treatment outcomes and enhance patient success rates.

Procedures segmentation in the ART market delineates the specific clinical interventions and treatment protocols utilized in fertility care. These procedures encompass a spectrum of fertility treatments tailored to individual patient needs, including ovarian stimulation, follicle monitoring, oocyte retrieval, sperm preparation, fertilization techniques, embryo transfer, and post-transfer care. Additionally, procedures may involve ancillary services such as genetic counseling, embryo biopsy, and surrogacy arrangements, depending on the unique circumstances of each patient.

Geographic segmentation in the ART market reflects regional variations in healthcare infrastructure, regulatory frameworks, patient demographics, and cultural attitudes toward fertility care. Major geographical regions include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Each region presents unique market dynamics and growth opportunities, influenced by factors such as population demographics, healthcare expenditure, reimbursement policies, and technological advancements in reproductive medicine.

Global Assistive Reproductive Technology Segment Analysis

In this report, the Global Assistive Reproductive Technology Market has been segmented by Product, Technology, Procedures, and Geography.

Global Assistive Reproductive Technology Market, Segmentation by Product

The Global Assistive Reproductive Technology Market has been segmented by Product into Consumables and Instruments.

Consumables play a pivotal role in the ART process, comprising a range of disposable supplies and materials necessary for conducting fertility treatments and laboratory procedures. These consumables include culture media, micropipettes, catheters, syringes, needles, and embryo transfer catheters, among others. Culture media, for instance, provide the essential nutrients and growth factors required for nurturing gametes and embryos in vitro, supporting their development and viability during the IVF and embryo culture stages. Micropipettes and catheters enable precise manipulation and transfer of gametes and embryos during procedures such as intracytoplasmic sperm injection (ICSI) and embryo transfer, ensuring optimal conditions for fertilization and implantation.

Instruments constitute the hardware and equipment utilized in ART laboratories and clinical settings to perform various assisted reproductive techniques and procedures. These instruments include micromanipulation systems, incubators, centrifuges, cryopreservation devices, and imaging systems, among others. Micromanipulation systems, such as micromanipulators and microinjectors, enable precise handling and manipulation of gametes and embryos during procedures like ICSI and embryo biopsy, ensuring accurate and controlled intervention at the cellular level. Incubators provide a controlled environment for maintaining optimal temperature, humidity, and gas concentrations during embryo culture, supporting their development until the transfer stage. Cryopreservation devices, including programmable freezers and vitrification equipment, enable the safe and long-term storage of gametes and embryos, allowing patients to preserve their fertility potential for future use.

Global Assistive Reproductive Technology Market, Segmentation by Technology

The Global Assistive Reproductive Technology Market has been segmented by Technology into In-vitro fertilization (IVF), Artificial Insemination-Intrauterine Insemination (AI-IUI), Frozen Embryo Replacement (FER), and Others.

In-vitro fertilization (IVF) stands as a cornerstone technology in the ART market, revolutionizing fertility care and enabling conception outside the human body. IVF involves the retrieval of eggs from the ovaries, fertilization with sperm in a laboratory setting, and subsequent transfer of embryos into the uterus. This technique offers a viable solution for couples facing various infertility issues, including tubal factor infertility, male factor infertility, and unexplained infertility, providing an opportunity for successful conception and pregnancy.

Artificial Insemination-Intrauterine Insemination (AI-IUI) represents another key technology in the ART market, offering a less invasive approach to fertility treatment compared to IVF. AI-IUI involves the direct placement of sperm into the woman's uterus during ovulation, bypassing potential barriers to fertilization and enhancing the chances of successful conception. This technique is particularly suitable for couples with male factor infertility, cervical factor infertility, or unexplained infertility, offering a cost-effective and relatively simple treatment option with high success rates.

Frozen Embryo Replacement (FER) technology plays a vital role in the ART market, enabling the storage and subsequent transfer of cryopreserved embryos to the uterus during an IVF cycle. FER allows patients to preserve surplus embryos generated during IVF treatment for future use, reducing the need for repeated ovarian stimulation and egg retrieval procedures. This technology offers flexibility and convenience for patients undergoing IVF, minimizing treatment costs and optimizing the chances of achieving a successful pregnancy.

Additionally, the ART market encompasses a range of other innovative technologies and procedures aimed at addressing specific fertility challenges and optimizing treatment outcomes. These may include techniques such as intracytoplasmic sperm injection (ICSI) for male factor infertility, preimplantation genetic testing (PGT) for embryo screening, and donor egg or sperm procedures for patients with gamete-related issues. Each technology offers unique benefits and advantages, tailored to the individual needs and circumstances of patients undergoing fertility treatment.

Global Assistive Reproductive Technology Market, Segmentation by Procedures

The Global Assistive Reproductive Technology Market has been segmented by Procedures into Fresh Donor, Frozen Donor, Fresh Nondonor, Embryo/Egg Banking, and Others.

Fresh Donor procedures represent a category of ART treatments involving the use of freshly donated gametes—either eggs or sperm—from altruistic donors to facilitate conception. In these procedures, donated gametes are collected from healthy, screened donors and subsequently utilized in fertility treatments such as in-vitro fertilization (IVF) or artificial insemination, providing individuals and couples with the opportunity to conceive and build families with the assistance of donor gametes.

Frozen Donor procedures involve the utilization of cryopreserved or frozen donated gametes—eggs or sperm—from anonymous or known donors to support assisted reproduction. Cryopreservation allows for the long-term storage of donor gametes, enabling patients to undergo fertility treatments such as IVF or intrauterine insemination (IUI) at their convenience, without the need for synchronous donor and recipient cycles, thereby optimizing treatment flexibility and efficiency.

Fresh Nondonor procedures encompass a range of fertility treatments and interventions that do not involve the use of donated gametes but instead rely on the individual's or couple's own gametes—eggs and sperm—to achieve conception. These procedures may include IVF, IUI, ovarian stimulation, follicle monitoring, and embryo transfer, among others, tailored to address various underlying causes of infertility and optimize treatment outcomes.

Embryo/Egg Banking procedures involve the cryopreservation and storage of surplus embryos or eggs generated during IVF treatment cycles for future use. Embryo and egg banking allows patients to preserve their fertility potential, defer embryo transfer or conception attempts, or undergo additional treatment cycles without the need for repeated ovarian stimulation and egg retrieval procedures, offering flexibility and convenience in family planning.

Additionally, the category of Others encompasses a variety of innovative and specialized ART procedures and interventions aimed at addressing specific fertility challenges and optimizing treatment outcomes. These may include techniques such as preimplantation genetic testing (PGT), embryo biopsy, assisted hatching, and intra-cytoplasmic morphologically selected sperm injection (IMSI), among others, tailored to the unique needs and circumstances of individual patients undergoing fertility treatment.

Global Assistive Reproductive Technology Market, Segmentation by Geography

In this report, the Global Assistive Reproductive Technology Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Assistive Reproductive Technology Market Share (%), by Geographical Region, 2023

North America represents a prominent region in the global ART market, characterized by advanced healthcare infrastructure, high levels of healthcare expenditure, and robust research and development activities in reproductive medicine. The region comprises countries such as the United States and Canada, where access to fertility treatments and assisted reproduction technologies is relatively widespread, supported by favorable regulatory frameworks, insurance coverage, and public awareness of infertility issues.

Europe stands as another significant market for ART, encompassing countries within the European Union (EU) such as Germany, France, the United Kingdom, and Spain, among others. The region boasts a diverse landscape of fertility clinics, research institutions, and specialized ART centers, catering to the needs of individuals and couples seeking fertility treatments. Access to ART services varies across European countries, influenced by factors such as reimbursement policies, cultural attitudes toward fertility, and regulatory standards governing assisted reproduction.

The Asia Pacific region presents substantial growth opportunities for the ART market, driven by rapid urbanization, changing lifestyles, and increasing awareness of fertility issues in countries such as China, India, Japan, and Australia. Despite variations in healthcare infrastructure and access to ART services across the region, demand for fertility treatments is on the rise, fueled by rising infertility rates, delayed childbearing, and greater acceptance of assisted reproduction technologies among Asian populations.

The Middle East and Africa region represent emerging markets for ART, characterized by evolving healthcare systems, varying cultural norms, and disparities in access to fertility care. While countries such as the United Arab Emirates (UAE), Saudi Arabia, and South Africa offer advanced medical facilities and specialized fertility clinics, access to ART services remains limited in many parts of the region, particularly in rural areas and underserved communities.

Latin America rounds out the geographical segmentation of the global ART market, encompassing countries such as Brazil, Mexico, Argentina, and Colombia, among others. The region exhibits a growing demand for fertility treatments and reproductive services, driven by demographic trends, socioeconomic factors, and increasing awareness of infertility issues. Access to ART services varies across Latin American countries, influenced by factors such as healthcare infrastructure, regulatory frameworks, and cultural attitudes toward fertility and family planning.

This report provides an in depth analysis of various factors that impact the dynamics of Global Assistive Reproductive Technology Market. These factors include; Market Drivers, Restraints, and Opportunities.

Drivers, Restraints and Opportunity Analysis

Drivers

• Increasing infertility prevalence
• Delayed childbearing trend
• Growing ART awareness and acceptance
• Cryopreservation and genetic screening innovations

• Demand for donor gametes and surrogacy - The demand for donor gametes and surrogacy serves as a significant driver in the global assistive reproductive technology (ART) market, reshaping the landscape of fertility treatments and family-building options for individuals and couples facing infertility challenges. Donor gametes, including eggs and sperm, offer a viable solution for individuals and couples unable to conceive using their own gametes due to various medical or genetic factors. This demand reflects the increasing prevalence of infertility worldwide and the growing acceptance of alternative reproductive pathways to achieve parenthood.

  Surrogacy, likewise, addresses the needs of individuals and couples unable to carry a pregnancy to term due to medical conditions or other factors. Surrogacy involves the use of a gestational carrier—either altruistic or compensated—to carry and deliver a baby on behalf of intended parents, utilizing either their own genetic material or donor gametes. The demand for surrogacy has surged in recent years, driven by factors such as delayed childbearing, same-sex parenting aspirations, and the desire for genetic connection in family-building efforts.

  The availability of donor gametes and surrogacy services expands the options and possibilities for individuals and couples seeking to build families through assisted reproduction. Donor gametes offer a solution for those facing challenges such as diminished ovarian reserve, sperm quality issues, genetic disorders, or single-parent family-building aspirations. Surrogacy provides an avenue for individuals and couples grappling with medical conditions such as uterine factor infertility, recurrent pregnancy loss, or contraindications to pregnancy to realize their dreams of parenthood.

Restraints

• Limited insurance coverage
• Rural clinic access limitations
• Psychological stress of infertility

• Health risks of multiple pregnancies - The health risks associated with multiple pregnancies serve as a significant restraint in the global assistive reproductive technology (ART) market, posing challenges for both patients and healthcare providers. Multiple pregnancies, commonly resulting from the transfer of multiple embryos during ART procedures such as in vitro fertilization (IVF), present elevated risks of maternal and fetal complications compared to singleton pregnancies.

  For expectant mothers, multiple pregnancies increase the likelihood of obstetric complications such as gestational diabetes, preeclampsia, placental abnormalities, and preterm birth. These complications can have serious implications for maternal health, requiring closer monitoring, specialized care, and increased medical interventions throughout the pregnancy and delivery process. Additionally, the physical strain of carrying multiple fetuses can exacerbate maternal discomfort, fatigue, and psychological stress, impacting the overall well-being and quality of life of expectant mothers.

  Multiple pregnancies pose heightened risks for fetal and neonatal health, including intrauterine growth restriction, congenital anomalies, and neonatal intensive care unit (NICU) admissions. Preterm birth, a common consequence of multiple gestations, increases the risk of respiratory distress syndrome, intraventricular hemorrhage, and long-term developmental disabilities in newborns. The management of multiple pregnancies requires vigilant monitoring, specialized prenatal care, and early intervention to mitigate these risks and optimize pregnancy outcomes for both mothers and babies.

Opportunities

• Fertility tourism growth
• Personalized fertility treatments
• Clinic-genetics company collaborations
• Fertility preservation advancements

• Employer-sponsored fertility benefits - Employer-sponsored fertility benefits represent a significant opportunity in the global assistive reproductive technology (ART) market, offering potential advantages for both employers and employees. As infertility becomes increasingly recognized as a prevalent medical condition affecting individuals and couples worldwide, the provision of fertility benefits by employers emerges as a strategic initiative to support employee well-being, enhance workplace inclusivity, and attract and retain top talent.

  For employers, offering fertility benefits presents an opportunity to demonstrate commitment to employee health and wellness, fostering a supportive work environment and reinforcing organizational values of inclusivity and diversity. By providing coverage for fertility treatments such as in vitro fertilization (IVF), intrauterine insemination (IUI), and fertility medications, employers can alleviate the financial burden of ART procedures for employees, reducing stress and anxiety associated with infertility and enhancing overall job satisfaction and productivity.

  Employer-sponsored fertility benefits can serve as a competitive advantage in talent acquisition and retention, especially in industries where attracting and retaining skilled professionals is critical to business success. By differentiating themselves as employers of choice with comprehensive benefits packages that include fertility coverage, companies can attract diverse talent pools and appeal to candidates seeking supportive workplace policies that align with their personal and family planning goals.

Key players in Global Assistive Reproductive Technology Market include,

• The Cooper Companies Inc (CooperSurgical)
• Vitrolife AB
• Cook Medical
• Merck KGaA (EMD Serono)
• Ferring Pharmaceuticals
• Irvine Scientific
• Origio
• Thermo Fisher Scientific Inc
• Genea Biomedx
• FUJIFILM Irvine Scientific
• IVFtech ApS
• Esco Micro Pte Ltd
• Progyny Inc
• Cryoport Inc
• OvaScience (Now Millendo Therapeutics)

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis